Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Review

Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review

Authors: Zhaoguo Han, Yongyi Wu, Kai Wang, Yadi Xiao, Zhen Cheng, Xilin Sun, Baozhong Shen

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

Mesenchymal–epithelial transition factor also named c-MET is a receptor tyrosine kinase for the hepatocyte growth factor that plays a pivotal role in tumorigenesis. c-MET-targeted therapies have been tested in preclinical models and patients, with significant benefits for cancer treatment. In recent years, many studies have shown that the expression level and activation status of c-MET are closely correlated to c-MET-targeted therapy response and clinical prognosis, thus highlighting the importance of evaluating the c-MET status during and prior to targeted therapy. Molecular imaging allows the monitoring of abnormal alterations of c-MET in real time and in vivo.

Results

In this review, we initially summarize the recent advances in c-MET-targeted molecular imaging, with a special focus on the development of imaging agents ranging in size from monoclonal antibody to small molecule. The aim of this review is to report the preclinical results and clinical application of all molecular imaging studies completed until now for in vivo detection of c-MET in cancer, in order to be beneficial to development of molecular probe and the combination of molecular imaging technologies for in vivo evaluation of c-MET. Various molecular probe targeted to c-MET possesses distinctive advantages and disadvantages. For example, antibody-based probes have high binding affinity but with long metabolic cycle as well as remarkable immunogenicity.

Conclusions

Although studies for c-MET-targeted molecular imaging have made many important advances, most of imaging agents specifically target to extracellular area of c-MET receptor; however, it is difficult to reflect entirely activation of c-MET. Therefore, small molecule probes based on tyrosine kinase inhibitors, which could target to intracellular area of c-MET without any immunogenicity, should be paid more attention.
Literature
1.
Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33.CrossRefPubMed
2.
Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504–16.CrossRefPubMed
3.
Gherardi E, Youles ME, Miguel RN, Blundell TL, Iamele L, Gough J, et al. Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 2003;100:12039–44.CrossRefPubMedPubMedCentral
4.
Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989;342:440–3.CrossRefPubMed
5.
Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun. 1989;163:967–73.CrossRefPubMed
6.
Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–42.CrossRefPubMed
7.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251:802–4.CrossRefPubMed
8.
Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915–25.CrossRefPubMed
9.
Rodrigues GA, Park M. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Oncogene. 1994;9:2019–27.PubMed
10.
Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem. 1996;271:13116–22.CrossRefPubMed
11.
Pelicci G, Giordano S, Zhen Z, Salcini AE, Lanfrancone L, Bardelli A, et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene. 1995;10:1631–8.PubMed
12.
Sakkab D, Lewitzky M, Posern G, Schaeper U, Sachs M, Birchmeier W, et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J Biol Chem. 2000;275:10772–8.CrossRefPubMed
13.
Garcia-Guzman M, Dolfi F, Zeh K, Vuori K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1-Crk signaling complex formation. Oncogene. 1999;18:7775–86.CrossRefPubMed
14.
15.
Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834–48.CrossRefPubMed
16.
Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs. 2008;17:997–1011.CrossRefPubMed
17.
Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657–60.CrossRefPubMed
18.
Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene. 2002;21:2309–19.CrossRefPubMed
19.
Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. 2001;98:247–52.CrossRefPubMed
20.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353:172–87.CrossRefPubMed
21.
Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225:1–26.CrossRefPubMed
22.
Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol. 1990;111:2097–108.CrossRefPubMed
23.
Rosen EM, Goldberg ID. Regulation of angiogenesis by scatter factor. EXS. 1997;79:193–208.PubMed
24.
Abounader R, Lal B, Luddy C, Koe G, Davidson B, Rosen EM, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16:108–10.PubMed
25.
26.
Wang R, Ferrell LD, Faouzi S, Maher JJ, Bishop JM. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 2001;153:1023–34.CrossRefPubMedPubMedCentral
27.
Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem. 2000;275:8806–11.CrossRefPubMed
28.
29.
Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499–508.CrossRefPubMed
30.
Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000;19:3041–9.CrossRefPubMed
31.
Yeh CY, Shin SM, Yeh HH, Wu TJ, Shin JW, Chang TY, et al. Transcriptional activation of the Axl and PDGFR-alpha by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer. 2011;11:139.CrossRefPubMedPubMedCentral
32.
Furge KA, Kiewlich D, Le P, Vo MN, Faure M, Howlett AR, et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc Natl Acad Sci U S A. 2001;98:10722–7.CrossRefPubMedPubMedCentral
33.
Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med. 2010;16:37–45.CrossRefPubMed
34.
Mueller KL, Hunter LA, Ethier SP, Boerner JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res. 2008;68:3314–22.CrossRefPubMed
35.
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, et al. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 2015;14:533–41.CrossRefPubMed
36.
Spigel DR, Edelman MJ, O’Byrne K, Paz-Ares L, Mocci S, Phan S, et al. Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. J Clin Oncol. 2017;35:412–20.CrossRefPubMed
37.
Yang R, Bunting S, Ko A, Schwall R, Jin H. Hemodynamic effects of scatter factor in conscious rats. J Cardiovasc Pharmacol. 1997;30:294–301.CrossRefPubMed
38.
Kaplan O, Firon M, Vivi A, Navon G, Tsarfaty I. HGF/SF activates glycolysis and oxidative phosphorylation in DA3 murine mammary cancer cells. Neoplasia. 2000;2:365–77.CrossRefPubMedPubMedCentral
39.
Shaharabany M, Abramovitch R, Kushnir T, Tsarfaty G, Ravid-Megido M, Horev J, et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res. 2001;61:4873–8.PubMed
40.
Tsarfaty G, Stein GY, Moshitch-Moshkovitz S, Kaufman DW, Cao B, Resau JH, et al. HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. Neoplasia. 2006;8:344–52.CrossRefPubMedPubMedCentral
41.
Luo H, Hong H, Slater MR, Graves SA, Shi S, Yang Y, et al. PET of c-Met in cancer with 64Cu-labeled hepatocyte growth factor. J Nucl Med. 2015;56:758–63.CrossRefPubMedPubMedCentral
42.
Corcoran EB, Hanson RN. Imaging EGFR and HER2 by PET and SPECT: a review. Med Res Rev. 2014;34:596–643.CrossRefPubMed
43.
Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, et al. Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor. Mol Imaging. 2002;1:56–62.CrossRefPubMed
44.
Hay RV, Cao B, Skinner RS, Su Y, Zhao P, Gustafson MF, et al. Nuclear imaging of Met-expressing human and canine cancer xenografts with radiolabeled monoclonal antibodies (MetSeek). Clin Cancer Res. 2005;11:7064s–9.CrossRefPubMed
45.
Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, et al. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res. 2003;9:3839S–44.PubMed
46.
Jiao Y, Zhao P, Zhu J, Grabinski T, Feng Z, Guan X, et al. Construction of human naive Fab library and characterization of anti-met Fab fragment generated from the library. Mol Biotechnol. 2005;31:41–54.CrossRefPubMed
47.
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, et al. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009;17:57–67.CrossRefPubMedPubMedCentral
48.
Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007;8:304–10.CrossRefPubMed
49.
Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008;29:193–207.CrossRefPubMed
50.
Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ, Leemans CR, et al. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857–67.CrossRefPubMed
51.
Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, et al. Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab. J Nucl Med. 2012;53:1592–600.CrossRefPubMedPubMedCentral
52.
Li K, Tavare R, Zettlitz KA, Mumenthaler SM, Mallick P, Zhou Y, et al. Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther. 2014;13:2607–17.CrossRefPubMedPubMedCentral
53.
Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 2011;32:3265–74.CrossRefPubMed
54.
Towner RA, Smith N, Doblas S, Tesiram Y, Garteiser P, Saunders D, et al. In vivo detection of c-Met expression in a rat C6 glioma model. J Cell Mol Med. 2008;12:174–86.CrossRefPubMedPubMedCentral
55.
Doblas S, Saunders D, Kshirsagar P, Pye Q, Oblander J, Gordon B, et al. Phenyl-tert-butylnitrone induces tumor regression and decreases angiogenesis in a C6 rat glioma model. Free Radic Biol Med. 2008;44:63–72.CrossRefPubMed
56.
Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, et al. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Mol Imaging. 2007;6:18–29.PubMed
57.
Towner RA, Smith N, Asano Y, Doblas S, Saunders D, Silasi-Mansat R, et al. Molecular magnetic resonance imaging approaches used to aid in the understanding of the tissue regeneration marker Met in vivo: implications for tissue engineering. Tissue Eng Part A. 2010;16:365–71.CrossRefPubMedPubMedCentral
58.
Hasebroock KM, Serkova NJ. Toxicity of MRI and CT contrast agents. Expert Opin Drug Metab Toxicol. 2009;5:403–16.CrossRefPubMed
59.
Thorek DL, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34:23–38.CrossRefPubMed
60.
61.
Zhao P, Grabinski T, Gao C, Skinner RS, Giambernardi T, Su Y, et al. Identification of a met-binding peptide from a phage display library. Clin Cancer Res. 2007;13:6049–55.CrossRefPubMed
62.
Kim EM, Park EH, Cheong SJ, Lee CM, Kim DW, Jeong HJ, et al. Characterization, biodistribution and small-animal SPECT of I-125-labeled c-Met binding peptide in mice bearing c-Met receptor tyrosine kinase-positive tumor xenografts. Nucl Med Biol. 2009;36:371–8.CrossRefPubMed
63.
Kim EM, Park EH, Cheong SJ, Lee CM, Jeong HJ, Kim DW, et al. In vivo imaging of mesenchymal-epithelial transition factor (c-Met) expression using an optical imaging system. Bioconjug Chem. 2009;20:1299–306.CrossRefPubMed
64.
Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam ML, Kales AJ, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015;21:955–61.CrossRefPubMed
65.
Liu S, Zheng Y, Volpi D, El-Kasti M, Klotz D, Tullis I, et al. Toward operative in vivo fluorescence imaging of the c-Met proto-oncogene for personalization of therapy in ovarian cancer. Cancer. 2015;121:202–13.CrossRefPubMed
66.
Arulappu A, Battle M, Eisenblaetter M, McRobbie G, Khan I, Monypenny J, et al. c-Met PET imaging detects early-stage locoregional recurrence of basal-like breast cancer. J Nucl Med. 2016;57:765–70.CrossRefPubMed
67.
Garcia-Allende PB, Glatz J, Koch M, Ntziachristos V. Enriching the interventional vision of cancer with fluorescence and optoacoustic imaging. J Nucl Med. 2013;54:664–7.CrossRefPubMed
68.
Jagoda EM, Bhattacharyya S, Kalen J, Riffle L, Leeder A, Histed S, et al. Imaging the Met receptor tyrosine kinase (Met) and assessing tumor responses to a Met tyrosine kinase inhibitor in human xenograft mouse models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) labeled peptide. Mol Imaging. 2015;14:499–515.PubMed
69.
Gross S, Piwnica-Worms D. Spying on cancer: molecular imaging in vivo with genetically encoded reporters. Cancer Cell. 2005;7:5–15.PubMed
70.
Razgulin A, Ma N, Rao J. Strategies for in vivo imaging of enzyme activity: an overview and recent advances. Chem Soc Rev. 2011;40:4186–216.CrossRefPubMed
71.
72.
Moshitch-Moshkovitz S, Tsarfaty G, Kaufman DW, Stein GY, Shichrur K, Solomon E, et al. In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. Neoplasia. 2006;8:353–63.CrossRefPubMedPubMedCentral
73.
Olwill SA, Joffroy C, Gille H, Vigna E, Matschiner G, Allersdorfer A, et al. A highly potent and specific MET therapeutic protein antagonist with both ligand-dependent and ligand-independent activity. Mol Cancer Ther. 2013;12:2459–71.CrossRefPubMed
74.
van Scheltinga AG T, Lub-de Hooge MN, Hinner MJ, Verheijen RB, Allersdorfer A, Hulsmeyer M, et al. In vivo visualization of MET tumor expression and anticalin biodistribution with the MET-specific anticalin 89Zr-PRS-110 PET tracer. J Nucl Med. 2014;55:665–71.CrossRef
75.
Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, et al. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One. 2013;8:e83232.CrossRefPubMedPubMedCentral
76.
Wu C, Tang Z, Fan W, Zhu W, Wang C, Somoza E, et al. In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor. J Med Chem. 2010;53:139–46.CrossRefPubMed
77.
Pool M, van Dam GM, de Vries EG. Emerging opportunities for c-MET visualization in the clinic. J Nucl Med. 2016;57:663–4.CrossRefPubMed
Metadata
Title
Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review
Authors
Zhaoguo Han
Yongyi Wu
Kai Wang
Yadi Xiao
Zhen Cheng
Xilin Sun
Baozhong Shen
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-017-0286-z

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue

Original research

[18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease

Letter to the Editor

Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer; methodological issues to avoid mismanagement of the patients

Letter to the Editor

Carotid atherosclerotic plaques standardized uptake values: methodological issues on reproducibility and accuracy

Original research

Evaluation of the novel TSPO radiotracer [18F] VUIIS1008 in a preclinical model of cerebral ischemia in rats

Original research

IDAC-Dose 2.1, an internal dosimetry program for diagnostic nuclear medicine based on the ICRP adult reference voxel phantoms

Original research

Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms